Payers and providers now expect RWE to complement trial efficacy by demonstrating effectiveness, utilization impact, and ROI ...
Formulary positioning and benefit design frequently determine utilization, as weak placement or reimbursement dynamics can ...
The latest IT offerings for sales force automation—including new AI tools—promise a more effective pharma sales process. Like many other aspects of healthcare, pharmaceutical sales and marketing ...
Integrated direct-to-patient models use AI-enabled eBenefits/eVerification plus real-time claims adjudication to surface ...
BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...
Supreme Court inaction leaves intact lower-court rulings rejecting takings and compelled-speech theories against “fair price” designations in Medicare price negotiation. Courts emphasized ...
Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.
Makary’s tenure aligned FDA with MAHA priorities, including advocating placebo-controlled Covid-19 vaccine trials in ...
In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook. Welcome to Pharma Pulse, ...
Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...
The trend is continuing for brands and even for some specialty products. Thanks to the reemergence of cash pharmacy, the two primary funding sources for medications in the US—patients and plan ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results